Rethinking Brain Health | MindMed
MindMed is a global leader in brain health innovation, developing novel drug candidates based on psychedelics and other compounds. Learn about their pipeline, programs, research, and …
- 预计阅读时间：1 分钟
仅显示来自 mindmed.co 的搜索结果Clinical Trials
Participants. Visit clinicaltrials.gov to find clinical trials near you. This site is a …
Programs & Research
MM120 orally disintegrating tablet (ODT) is MindMed’s proprietary and …
Investors
MindMed is a clinical stage biopharmaceutical company developing …
About Us
Meet MindMed's team of experts, who are at the core of our mission to be the …
News & Media
MindMed to Be Added to the Nasdaq Biotechnology Index. Dec 16, 2024 7:00 …
Careers
We look for candidates who embody MindMed’s corporate values: We are …
Contact Us
MindMed is a clinical-stage biopharmaceutical company developing …
Privacy Policy
MindMed may share your PII with recipients outside of MindMed if we have a good …
Mind Medicine (MindMed) Inc. (MNMD) - Yahoo Finance
MindMed is a clinical stage biopharmaceutical company developing products for brain health disorders. Get the latest stock price, news, performance, valuation and statistics for MNMD on Yahoo Finance.
Mind Medicine (MindMed) Inc. (MNMD)
2024年12月11日 · MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the …
MindMed Inc. - Wikipedia
Mind Medicine (MindMed) Inc., doing business as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Wikipedia · CC-BY-SA 许可下的文字MindMed Announces First Patient Dosed in Phase 3 Voyage Study …
2024年12月16日 · NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company …
Programs & Research - MindMed
MM120 orally disintegrating tablet (ODT) is MindMed’s proprietary and pharmaceutically optimized form of lysergide D-tartrate, which is also known as LSD. MM120 ODT is an advanced formulation incorporating Catalent’s Zydis …
MindMed Receives FDA Breakthrough Therapy …
2024年3月7日 · MindMed, a biopharmaceutical company developing novel products for brain health disorders, reports positive results from its Phase 2b study of MM120, a single-dose oral treatment for generalized anxiety disorder. …
MindMed Receives FDA Breakthrough Therapy …
2024年3月7日 · MindMed, a biopharmaceutical company developing novel treatments for brain health disorders, reports positive results from its Phase 2b study of MM120, a single-dose oral therapy for generalized anxiety disorder. …
FDA Clears MindMed IND for MM-120 in Treatment of …
2022年1月25日 · MindMed is developing psychedelic-inspired therapies for brain-based disorders, including MM-120, a form of LSD for generalized anxiety disorder. The FDA cleared MindMed's IND for MM-120, allowing the initiation …
MindMed - LinkedIn
MindMed is a public company that develops novel products to treat psychiatry, addiction, pain and neurology. It has a pipeline of drug candidates, including MM120, a lysergide-based treatment …
Mindmed 的相关搜索
